Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brazil thanks early malaria diagnoses for US$3m savings

This article was originally published in Clinica

Executive Summary

Further evidence of the cost benefits of prompt management of malaria cases was cited this week by the Brazilian health ministry to highlight the importance of early diagnosis. The number of hospitalisations fell by a total of 40,000 during 2002-07, compared with levels expected from previous years, with the introduction of the national malaria programme, said the health ministry. During 1998-2001, annual hospitalisations for malaria averaged almost 19,000. By 2007, these had fallen to just over 6,300, compared with an expected 16,400. The cost savings of these reductions total almost R$6.9m (US$3m). The programme is also reducing significantly the number of infections, according to the health ministry. In Amazonia Legal state alone, 267,000 cases were reported in the first 10 months of 2008, compared with almost 400,000 during the same period the year before.

You may also be interested in...

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts